Home » Topics » BioWorld Science

BioWorld Science
RSS

WX-UK1: the first urokinase inhibitor to enter clinical trials

Sep. 25, 2001

Postponement of 41st ICAAC meeting until December

Sep. 25, 2001

Orally active antiinflammatory agents from Pharmacia selectively inhibit COX-2

Sep. 25, 2001

Thyroid hormone receptor modulator commences human safety trials

Sep. 25, 2001

AstraZeneca presents new antiarrhythmic agents with class III activity

Sep. 25, 2001

Pyrrole and pyrrolidine derivatives as PDE4 and TNF production inhibitors

Sep. 25, 2001

New anti-HIV agents with low cytotoxicity

Sep. 25, 2001

Glycopeptides from Advanced Medicine active against resistant Gram-positive pathogens

Sep. 25, 2001

Modified doxorubicins and daunorubicins suitable for use in immunoconjugates

Sep. 25, 2001

Pharmacokinetic/pharmacodynamic studies support further development of insulin Spiros

Sep. 25, 2001

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 18, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 16, 2026
Gene replacement rescues autism-related phenotypes in mice
BioWorld Science
Autism spectrum disorder (ASD), developmental epileptic encephalopathies and other neurodevelopmental disorders are driven by the disruption of genes regulating...
For clonal hematopoiesis, epigenetics can be in driver’s seat
BioWorld Science
Clonal hematopoiesis (CH), where few blood stem cells produce a significant fraction of mature blood cells that are genetically identical, is partly an inevitable...
Elixiron’s enrupatinib shows upbeat interim phase II AD results
BioWorld
Elixiron Immunotherapeutics Inc. announced positive interim open-label phase II Alzheimer’s disease (AD) study findings of enrupatinib, an oral brain-penetrant...